[Effect of systemic thrombolytic therapy on necrotic focus formation in myocardial infarct patients].
The formation of the myocardial necrotic focus was assessed by precardial charting at 35 leads and the serial determination of CPK activity and MB fraction in 50 patients receiving the systemic thrombolytic therapy and 52 patients of the control group. Thrombolytic therapy initiated within the first 6 h of the disease was shown to facilitate the limitation of the extent of myocardial infarction through a more rapid stabilization of the necrotic focus. The calculated extent of myocardial infarction in patients treated with thrombolytic drugs was 37.4% less than in the control group. A beneficial clinical effect of thrombolytic therapy was demonstrated.
D000328:Adult; D000368:Aged; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D009206:Myocardium / Q000473:pathology*; D009336:Necrosis; D013300:Streptokinase / Q000008:administration & dosage; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage
D005343:Fibrinolytic Agents; D007527:Isoenzymes; D003402:Creatine Kinase; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator
Vliianie sistemnoĭ tromboliticheskoĭ terapii na formirovanie ochaga nekroza u bol'nykh infarktom miokarda.